Content about Bronchodilators

January 10, 2014

The Nonprescription Drugs Advisory Committee announced it would meet February 25 to discuss data submitted by Armstrong Pharmaceuticals in support of a new drug application for the over-the-counter marketing of Primatene HFA.

SILVER SPRING, Md. — The Nonprescription Drugs Advisory Committee on Thursday announced it would meet February 25 to discuss data submitted by Armstrong Pharmaceuticals in support of a new drug application for the over-the-counter marketing of Primatene HFA, an epinephrine inhalation aerosol 125 microgram (mcg)/actuation, as a temporary reliever of mild symptoms of intermittent asthma for consumers 12 years of age and older. 

October 23, 2013

The Food and Drug Administration plans to complete its phase out of inhalers that contain ozone-depleting chlorofluorocarbons by the end of the year, the agency said Wednesday.

SILVER SPRING, Md. — The Food and Drug Administration plans to complete its phase out of inhalers that contain ozone-depleting chlorofluorocarbons by the end of the year, the agency said Wednesday.

September 18, 2012

Boehringer Ingelheim Pharmaceuticals has launched a drug for treating chronic obstructive pulmonary disease, the company said Tuesday.

RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals has launched a drug for treating chronic obstructive pulmonary disease, the company said Tuesday.

BI Pharmaceuticals announced the launch of Combivent Respimat (ipratropium bromide and albuterol), calling it a propellant-free inhaler that uses a slow-moving mist to deliver the same active ingredients as the Combivent metered dose inhaler, requiring one inhalation per dose, compared with Combivent MDI's two inhalations.

August 20, 2012

Prasco Labs is distributing an authorized generic version of a respiratory drug under an agreement with the branded drug's manufacturer.

CINCINNATI, Ohio — Prasco Labs is distributing an authorized generic version of a respiratory drug under an agreement with the branded drug's manufacturer.

July 24, 2012

The Food and Drug Administration has approved a new drug made by Forest Labs for treating chronic obstructive pulmonary disease, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Forest Labs for treating chronic obstructive pulmonary disease, the agency said.

The FDA announced the approval of Tudorza Pressair (aclidinium bromide) for the long-term maintenance of COPD-related narrowing of the airways in the lung, also known as bronchospasm. The drug is an inhaled dry powder used twice per day.

June 21, 2012

Taken together, asthma and chronic obstructive pulmonary disease — which includes chronic bronchitis and emphysema — affect nearly 50 million Americans, or about 15% of the total U.S. population, according to statistics from such organizations as the Centers for Disease Control and Prevention.

Taken together, asthma and chronic obstructive pulmonary disease — which includes chronic bronchitis and emphysema — affect nearly 50 million Americans, or about 15% of the total U.S. population, according to statistics from such organizations as the Centers for Disease Control and Prevention. And combined, the two diseases cause more than 100,000 deaths per year. Fortunately, however, there is a wide range of treatments available for both, many of which work for both diseases.


May 29, 2012

A unit of generic drug maker Mylan has settled with Sunovion Pharmaceuticals over a drug used to treat chronic obstructive pulmonary disease and asthma.

PITTSBURGH — A unit of generic drug maker Mylan has settled with Sunovion Pharmaceuticals over a drug used to treat chronic obstructive pulmonary disease and asthma.

Mylan announced Tuesday that it had reached a settlement in a patent litigation suit that Sunovion, which used to operate under the name Sepracor, had filed against Dey Pharma, now known as Mylan Specialty, concerning the drug Xopenex (levalbuterol hydrochloride).

March 9, 2012

The Food and Drug Administration has approved a version of a drug made by Teva that includes a dose counter, the drug maker said.

NORTH WALES, Pa. — The Food and Drug Administration has approved a version of a drug made by Teva that includes a dose counter, the drug maker said.

Teva announced the approval of the inhaled drug ProAir HFA (albuterol sulfate) with a dose counter for treating bronchospasm with reversible obstructive airway disease and preventing exercise-induced bronchospasm in patients ages 4 years and older. The dose counter is designed to help patients and caregivers keep track of the number of doses in the canister.

February 17, 2012

One of the main plotlines of the big story called the drug industry over the past several years has been the patent cliff, the steady loss of patent protection on blockbuster primary care drugs and subsequent generic competition that has forced many drug companies to find new revenue streams.

One of the main plotlines of the big story called the drug industry over the past several years has been the patent cliff, the steady loss of patent protection on blockbuster primary care drugs and subsequent generic competition that has forced many drug companies to find new revenue streams. Much of this has taken place in the form of a gradual shift to specialty drugs for such conditions as cancers and autoimmune disorders, but recent developments have shown that primary care drugs may still have some steam left in them.


February 14, 2012

Generic drug maker Mylan plans to challenge a court decision that requires it to pay almost $20 million to a drug company whose product it tried to market as a generic.

PITTSBURGH — Generic drug maker Mylan plans to challenge a court decision that requires it to pay almost $20 million to a drug company whose product it tried to market as a generic.

Sunovion Pharmaceuticals sued Mylan and several subsidiaries in the U.S. District Court for the District of Delaware when the latter sought to market a generic version of Sunovion's Xopenex (levalbuterol hydrochloride) inhalation solution, a drug for asthma and chronic obstructive pulmonary disease. The jury's verdict includes an $18 million award.

October 10, 2011

The Food and Drug Administration has approved a new product for chronic obstructive pulmonary disease made by Boehringer Ingelheim Pharmaceuticals, the drug maker said.

RIDGEFIELD, Conn. — The Food and Drug Administration has approved a new product for chronic obstructive pulmonary disease made by Boehringer Ingelheim Pharmaceuticals, the drug maker said.

September 22, 2011

Epinephrine inhalers will not be made or sold after Dec. 31, and patients using them should get new prescriptions to replace them, the Food and Drug Administration said Thursday.

SILVER SPRING, Md. — Epinephrine inhalers will not be made or sold after Dec. 31, and patients using them should get new prescriptions to replace them, the Food and Drug Administration said Thursday.

Epinephrine inhalers, which Armstrong Pharmaceutical markets under the brand name Primatene Mist, are used to relieve symptoms of mild asthma and are sold over-the-counter.

April 12, 2010

The Food and Drug Administration will start phasing out asthma and chronic obstructive pulmonary disease...

SILVER SPRING, Md. The Food and Drug Administration will start phasing out asthma and chronic obstructive pulmonary disease inhalers that contain ozone-depleting chlorofluorocarbons in less than two months, the agency announced Tuesday.

 

February 1, 2010

A drug from Boehringer Ingelheim and Pfizer will retain Decision Resources’ status as a gold...

January 13, 2010

Data from a recent review of a treatment for chronic obstructive pulmonary disease do not...